Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taste Profile and Bioavailability of Belumosudil Oral Suspensions in Healthy Males
NCT04735822Phase 1Completed
- Sponsor
- Kadmon
- Start
- Oct 2020
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of belumosudil in chronic graft-versus-host disease (cGVHD) (12 arms), sponsored by Kadmon. Primary endpoints: Comparison of Taste/Palatability Questionnaire and Selection of Belumosudil Suspension Formulation for Part 2. Started Oct 2020; status: completed.
02
Drugs
belumosudil
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT04735822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04735822.